Pharming to sound the gong to open Amsterdam market to mark a summer of significant strategic progress for PharmingPublished : Tuesday, September 2, 2014
Pharming and Salix announce initiation of clinical study of RUCONEST® for prophylaxis of hereditary angioedemaPublished : Thursday, August 28, 2014
Pharming acquires new product leads through the acquisition of certain assets of TRM SASU for € 0.5 Million in cashPublished : Tuesday, August 19, 2014
Biotech company Pharming Group NV announced that through the acquisition of certain assets of Transgenic Rabbit Models SASU (TRM), a private French company in liquidation; for € 0.5 million in cash, it has gained access to five potential new product leads (founder rabbits); recombinant- human (rh)-α-glucosidase for the treatment of Pompe’s disease, rh-α-galactosidase for the treatment of Fabry’s disease, rh-β-cerebrosidase for the treatment of Gaucher’s disease, rh- Factor VIII for the treatment of Haemophilia-A and rh- Factor IX for the treatment of Haemophilia-B.
Dutch drug developer ProQR Therapeutics is swinging for a $75 million Wall Street debut to fund its work on a treatment for cystic fibrosis, looking to compete with market leader Vertex Pharmaceuticals ($VRTX). The company, co-founded by former Genzyme CEO Henri Termeer, is preparing a first clinical trial for its lead candidate, QR-010, an RNA-based therapy for CF.
Prosensa and CureDuchenne strengthen long-term collaboration with an additional € 5million to advance DMD pipelinePublished : Monday, August 11, 2014
Prosensa Holding N.V., the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that an affiliate of CureDuchenne, a US national nonprofit organization dedicated to finding a cure for Duchenne Muscular Dystrophy (DMD), will provide Prosensa with up to €5 million by means of convertible promissory notes to support the company and accelerate the development and patient access of much needed DMD therapies. The closing of €4.5 million of the notes is contingent upon specified milestones in the advancement of drisapersen and the Company's other exon skipping candidates in Prosensa's DMD portfolio.
Galapagos NV announced the achievement of a second partial milestone, thereby completing the nomination of a new pre-clinical candidate in the osteoarthritis alliance with Servier. On March 7, Galapagos announced the receipt of €2M as the first partial milestone. Today's payment remains undisclosed and contributes to Group revenues in the first half of 2014.
The FP7 Health project ENTENTE and EuropaBio event will gather 28 European early stage innovative companies active in the health sector and seeking investment opportunities and international exposure. The selected companies will have the opportunity to pitch their innovation, developments and needs to an international jury of about 40 business angels, venture capitalists, corporate investors and other industry experts. The deadline for applications is 29 August.
For his research on poisonous snakes Dr. Freek Vonk, researcher at Naturalis Biodiversity Center, received a VENI grant of a quarter million from the Dutch Organization for Scientific Research (NWO). Freek Vonk will use this amount to clarify the genomes of two species of poisonous snake species.
> Read more Dutch
MorphoSys and Galapagos advance Joint antibody program in Inflammatory diseases into preclinical developmentPublished : Wednesday, July 23, 2014
MorphoSys AG and Galapagos NV announced that the first program from their strategic alliance has advanced into preclinical development. MOR106 was realized based on a novel Galapagos target and MorphoSys' next-generation antibody library Ylanthia and will now be jointly developed in inflammatory diseases.
Pharming and Salix announce FDA approval of Ruconest® for the treatment of acute Angioedema Attacks in patients with Hereditary Angioedema (HAE)Published : Thursday, July 17, 2014
Pharming Group NV and Salix Pharmaceuticals, Ltd. announced that the Food and Drug Administration has approved RUCONEST® (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE). Because of the limited number of patients with laryngeal attacks, effectiveness was not established in HAE patients with laryngeal attacks.
One of the riddles of mammal evolution explained: the strong conservation of the number of trunk vertebrae. Researchers of the Naturalis Biodiversity Center and the University of Utah show that this conservation is probably due to the essential role of speed and agility in survival of fast running mammals.
The first two courses of the Leiden Futurelab, a new international post-graduate learning center for biomedical professionals with an entrepreneurial spirit, took place in June and early July. Both courses were very successful: 'Clinical development & clinical trial application' (CD&CTA) and 'Intellectual Property in high tech start-ups' (IP). The courses offered a stimulating environment for the participants.
Leiden Bio Science Park and InnovationQuarter together with other regional organizations joined the Dutch Ministry and Holland Bio at the Holland Pavilion at the BIO International Convention 2014 in San Diego. In this joined effort The Netherlands was well represented and profiled as a biotech hub for international companies at the world’s largest and most prestigious biotechnology event.
The Leiden Bio Science Park newsletter is a free bimonthly email newsletter in English. The newsletter offers general life science news, news from the companies and institutions, a company profile, events and jobs.
click here to subscribe